29 patents currently held
50 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Nov 2028. from the record
Of the 50 now held by other companies, 22 were conveyed to Rani Therapeutics LLC in the filing they arrived in, and 28 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
5
Ending by 2030
Nov 2028
Next term end
20
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Sep 2030 · High confidence
Also notable
Ends Jan 2029 · High confidence
Also notable
Ends Mar 2037 · High confidence
Patch and Patch Assembly for Iontophoretic Transdermal Delivery of Active Agents for Therapeutic and Medicinal Purposes
US 8,903,485
The most cited patent in this portfolio, cited by 42 later US patents, top 25% of utility patents granted in 2014 in our data. Protection runs to 2030.
Method for the Detection and Treatment of Aberrant Neural-Electric Activity
US 10,264,987
Cited by 14 later US patents, top 25% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2029. A terminal disclaimer caps this term to an earlier patent's.
Methods and Articles for Delivering Viable Cells into Solid Tissue
US 10,220,003
Cited by 21 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2037.
Formerly held, still cited
Notable
Ends Dec 2030 · High confidence
Cited by 144 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2030.
conveyed to Rani Therapeutics, LLC
Also notable
Ends Jul 2031 · High confidence
Cited by 207 later US patents, top 5% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
now held by Rani Therapeutics, LLC
Also notable
Ends Sep 2036 · High confidence
Cited by 22 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2036.
now held by Rani Therapeutics, LLC
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 11, 2026The maintenance fee for Methods for Delivery of Optical Signals to Tissue for the Treatment of a Disease or Condition (US 10,315,044) comes due Dec 11, 2026. Unpaid by Jun 11, 2027, it lapses early.
- 1 fee due Feb 4, 2027The maintenance fee for System and Method for Biphasic Transdermal Iontophreotic Delivery of Therapeutic Agents (US 9,095,503) comes due Feb 4, 2027. Unpaid by Aug 4, 2027, it lapses early.
- 2 fees due Mar 3 to 29, 2027 · next Mar 3
- 3 fees due Apr 10 to 24, 2027 · next Apr 10
- 1 fee due May 12, 2027The maintenance fee for Systems and Methods for Patient-Enabled Bladder Control (US 10,471,255) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
- 1 fee due Aug 4, 2027The maintenance fee for Methods and Articles for Delivering Viable Cells into Solid Tissue (US 10,548,851) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
- 1 fee due Sep 17, 2027The maintenance fee for Urethral Catheters and Methods for Facilitated Introduction into the Urinary Tract (US 10,589,093) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.
- 1 fee due Oct 2, 2027The maintenance fee for Multi-Stage Biodegradable Drug Delivery Platform (US 11,944,780) comes due Oct 2, 2027. Unpaid by Apr 3, 2028, it lapses early.
Recent changes
- 3 terms have ended since Aug 18, 2026
What they patent
The 5 largest of its 20 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Method for treating glucose related disorders using stem cell-derived gastro-intestinal cells | 4 in force | to Dec 2032 |
| Apparatus for Manufacturing Microtablets | 2 in force | to May 2042 |
| Device, Systems and Methods for Treatment of Neurogenic Bladder | 2 in force | to Apr 2042 |
| Methods and Articles for Delivering Viable Cells into Solid Tissue | 2 in force | to Mar 2037 |
| Multi-Stage Biodegradable Drug Delivery Platform | 2 in force | to Mar 2034 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,315,044 | Methods for Delivery of Optical Signals to Tissue for the Treatment of a Disease or Condition In force · High confidence | In force | High confidence | |
| US 10,264,987 | Method for the Detection and Treatment of Aberrant Neural-Electric Activity In force · High confidence | In force | High confidence | |
| US 11,331,424 | Apparatus, Systems and Methods for Delivery of Medication to the Brain to Treat Neurological Conditions In force · High confidence | In force | High confidence | |
| US 9,095,503 | System and Method for Biphasic Transdermal Iontophreotic Delivery of Therapeutic Agents In force · High confidence | In force | High confidence | |
| US 8,903,485 | Patch and Patch Assembly for Iontophoretic Transdermal Delivery of Active Agents for Therapeutic and Medicinal Purposes In force · High confidence | In force | High confidence | |
| US 8,986,279 | Methods and Architecture for Power Optimization of Iontophoretic Transdermal Drug Delivery In force · High confidence | In force | High confidence | |
| US 10,398,737 | Method for Treating Diabetes and Other Glucose Regulation Disorders Using Stem Cells In force · Low confidence | In force | Low confidence | |
| US 11,077,146 | Method for Treating Diabetes and Other Glucose Regulation Disorders Using Stem Cells In force · Low confidence | In force | Low confidence | |
| US 9,144,586 | Method for treating glucose related disorders using stem cell-derived gastro-intestinal cells In force · High confidence | In force | High confidence | |
| US 10,172,997 | Implantable Solid-Liquid Drug Delivery Apparatus, Formulations, and Methods of Use In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 29: 50 patents in force now held by others · 99 patents ended · 9 applications pending · 52 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.